---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-26-000043"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:17:18.526808+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo

## Summary
- Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
- FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.
- U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.
- Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.
- Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D.

## SEC filing metadata
- accession: 0000059478-26-000043
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/lly-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-26-000043
- JSON: https://secwatch.observer/filing/0000059478-26-000043.json
- Plain text: https://secwatch.observer/filing/0000059478-26-000043.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported FY 2026 results: revenue 82.0 billion to 85.0 billion, EPS 35.50 to 37.00. Guidance raised.
  - Period: FY 2026
  - Revenue: 82.0 billion to 85.0 billion
  - EPS: 35.50 to 37.00
  - Guidance: raised
  - Result: guidance update
  source text: Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm
- Earnings Releases
  ELI LILLY & Co reported Q1 2026 results: revenue 19,799, net income 7,396, EPS 8.26.
  - Period: Q1 2026
  - Revenue: 19,799
  - Net income: 7,396
  - EPS: 8.26
  - Result: reported results
  source text: Revenue $ 19,799 $ 12,729 56% Net income – Reported 7,396 2,759 168% Earnings per share – Reported 8.26 3.06 170%
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.